HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target
Kala Pharmaceuticals, Inc. +8.12%
Kala Pharmaceuticals, Inc. KALA | 6.79 | +8.12% |
HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:
KALA) with a Buy and maintains $15 price target.